Table 1 Characteristics of the study population.
Non-user | User of TNF-α | |
|---|---|---|
Study population, N | 1,520,304 | 7,645 |
Patients with psoriasis, N (%) | 346,133 (22.8) | 1,213 (15.9) |
Patients with RA, N (%) | 1,194,277 (78.6) | 6,933 (90.7) |
Usagea, b [times], mean (range) | 20.2 (1-208) | |
Type of anti-TNFα [Used], N (%) | ||
Etanercept | - | 2,078 (27.2) |
Infliximab | - | 1,687 (22.1) |
Adalimumab | - | 3,453 (45.2) |
Golimumab | - | 1,113 (14.6) |
Age [years], mean ± SD | 56.25 (15.52) | 45.47 (14.76) |
Age [years], N (%) | ||
20–39 | 234,741 (15.4) | 2,887 (37.8) |
40–59 | 643,320 (42.3) | 3,324 (43.5) |
60–79 | 547,511 (36.0) | 1,366 (17.9) |
≥ 80 | 94,732 (6.2) | 68 (0.9) |
Sex, N (%) | ||
Men | 575,765 (37.9) | 4,452 (58.2) |
Women | 944,539 (62.1) | 3,193 (41.8) |
Income level, quartile, N (%) | ||
L1 (Lowest) | 498,434 (32.8) | 2,441 (31.9) |
L2 | 357,905 (23.5) | 1,920 (25.1) |
L3 | 288,698 (19.0) | 1,542 (20.2) |
L4 (Highest) | 375,267 (24.7) | 1,742 (22.8) |
Charlson comorbidity index, N (%) | ||
0–2 | 1,124,924 (74.0) | 6,001 (78.5) |
3–5 | 317,807 (20.9) | 1,392 (18.2) |
≥ 6 | 77,573 (5.1) | 252 (3.3) |
Other drug prescriptions [Used], N (%) | ||
Azathioprin | 8,318 (0.6) | 358 (4.7) |
Cyclophosphamide | 1,045 (0.1) | 14 (0.2) |
Cyclosporin | 37,503 (2.5) | 366 (4.8) |
Methotrexate | 87,607 (5.8) | 4,489 (58.7) |
